| Application number | Title of the application | Filing Date | Status |
|---|
Array
(
[id] => 17228648
[patent_doc_number] => 20210355204
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-18
[patent_title] => Antibodies Specific for TGF-Beta
[patent_app_type] => utility
[patent_app_number] => 17/376933
[patent_app_country] => US
[patent_app_date] => 2021-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53193
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -48
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17376933
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/376933 | Antibodies that bind transforming growth factor beta (TGF beta) and methods of use thereof for treatment | Jul 14, 2021 | Issued |
Array
(
[id] => 18612392
[patent_doc_number] => 20230279124
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => FUSION PROTEIN COMPRISING IGE FC RECEPTOR ALPHA SUBUNIT EXTRACELLULAR DOMAIN AND ANTI-IL-4R ANTIBODY, AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/005752
[patent_app_country] => US
[patent_app_date] => 2021-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7778
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18005752
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/005752 | FUSION PROTEIN COMPRISING IGE FC RECEPTOR ALPHA SUBUNIT EXTRACELLULAR DOMAIN AND ANTI-IL-4R ANTIBODY, AND USE THEREOF | Jul 13, 2021 | Pending |
Array
(
[id] => 18565785
[patent_doc_number] => 20230256112
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/017167
[patent_app_country] => US
[patent_app_date] => 2021-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56945
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18017167
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/017167 | ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF | Jul 8, 2021 | Pending |
Array
(
[id] => 17314502
[patent_doc_number] => 20210403550
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => FORMULATION OF TOCILIZUMAB AND METHOD FOR TREATING COVID-19 BY INHALATION
[patent_app_type] => utility
[patent_app_number] => 17/361651
[patent_app_country] => US
[patent_app_date] => 2021-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10393
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17361651
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/361651 | Formulation of tocilizumab and method for treating COVID-19 by inhalation | Jun 28, 2021 | Issued |
Array
(
[id] => 17171734
[patent_doc_number] => 20210325404
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => METHODS FOR PERFORMING EX VIVO DIAGNOSTIC TESTS FOR THE PRESENCE OF A PROLIFERATION-INDUCING LIGAND (APRIL) IN A HUMAN SAMPLE
[patent_app_type] => utility
[patent_app_number] => 17/360719
[patent_app_country] => US
[patent_app_date] => 2021-06-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18958
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 298
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17360719
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/360719 | Methods for performing ex vivo diagnostic tests for the presence of a proliferation-inducing ligand (APRIL) in a sample | Jun 27, 2021 | Issued |
Array
(
[id] => 19418491
[patent_doc_number] => 20240294614
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => ANTI-HENIPAVIRUS MONOCLONAL ANTIBODY HAVING BROAD SPECTRUM NEUTRALIZATION ACTIVITY AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/005979
[patent_app_country] => US
[patent_app_date] => 2021-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5598
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 121
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18005979
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/005979 | Monoclonal antibodies against Henipavirus glycoprotein G and encoding nucleic acids thereof | Jun 26, 2021 | Issued |
Array
(
[id] => 18709208
[patent_doc_number] => 20230331820
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => HSV gE ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/010258
[patent_app_country] => US
[patent_app_date] => 2021-06-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42789
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18010258
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/010258 | HSV gE ANTIBODIES | Jun 24, 2021 | Pending |
Array
(
[id] => 18529980
[patent_doc_number] => 20230235048
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => ANTIBODIES RECOGNIZING SORTILIN
[patent_app_type] => utility
[patent_app_number] => 18/011764
[patent_app_country] => US
[patent_app_date] => 2021-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61908
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -136
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18011764
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/011764 | ANTIBODIES RECOGNIZING SORTILIN | Jun 22, 2021 | Pending |
Array
(
[id] => 17260049
[patent_doc_number] => 20210373034
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-02
[patent_title] => Methods of Assigning a COVID Pathological Type and Compositions for Practicing the Same, and Methods of Treating a Subject for Chronic COVID-19
[patent_app_type] => utility
[patent_app_number] => 17/351055
[patent_app_country] => US
[patent_app_date] => 2021-06-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18637
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17351055
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/351055 | Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist | Jun 16, 2021 | Issued |
Array
(
[id] => 18468867
[patent_doc_number] => 20230203150
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => Methods and Treatment Involving Antibodies to IL-18
[patent_app_type] => utility
[patent_app_number] => 17/928427
[patent_app_country] => US
[patent_app_date] => 2021-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16338
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17928427
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/928427 | Methods and Treatment Involving Antibodies to IL-18 | May 30, 2021 | Pending |
Array
(
[id] => 18530019
[patent_doc_number] => 20230235087
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => ANTI-GD2 SADA CONJUGATES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/999786
[patent_app_country] => US
[patent_app_date] => 2021-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32497
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999786
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/999786 | ANTI-GD2 SADA CONJUGATES AND USES THEREOF | May 25, 2021 | Pending |
Array
(
[id] => 18420196
[patent_doc_number] => 20230174657
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => COMPOSITIONS COMPRISING AN ANTIBODY AGAINST INTERLEUKIN-6 RECEPTOR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME
[patent_app_type] => utility
[patent_app_number] => 17/926018
[patent_app_country] => US
[patent_app_date] => 2021-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16175
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926018
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/926018 | COMPOSITIONS COMPRISING AN ANTIBODY AGAINST INTERLEUKIN-6 RECEPTOR FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME | May 24, 2021 | Pending |
Array
(
[id] => 18484985
[patent_doc_number] => 20230212300
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => HUMAN ENDOTHELIN RECEPTOR A (ETAR) ANTAGONIST ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/926295
[patent_app_country] => US
[patent_app_date] => 2021-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32630
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17926295
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/926295 | HUMAN ENDOTHELIN RECEPTOR A (ETAR) ANTAGONIST ANTIBODIES | May 18, 2021 | Issued |
Array
(
[id] => 18093180
[patent_doc_number] => 20220411521
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => POLYPEPTIDES THAT BIND GLUCOCORTICOID-INDUCED TNFR FAMILY-RELATED RECEPTOR (GITR)
[patent_app_type] => utility
[patent_app_number] => 17/320395
[patent_app_country] => US
[patent_app_date] => 2021-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63559
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320395
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/320395 | Methods for inhibiting tumor growth or treating cancer by administering an immunoglobulin single variable domain that binds glucocorticoid-induced TNFR family-related receptor (GITR) | May 13, 2021 | Issued |
Array
(
[id] => 18931001
[patent_doc_number] => 11883395
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-30
[patent_title] => Method of treating severe acute respiratory syndrome (SARS) virus infection by administering a protein disulfide isomerase (PDI) inhibitor
[patent_app_type] => utility
[patent_app_number] => 17/320069
[patent_app_country] => US
[patent_app_date] => 2021-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 3
[patent_no_of_words] => 11915
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320069
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/320069 | Method of treating severe acute respiratory syndrome (SARS) virus infection by administering a protein disulfide isomerase (PDI) inhibitor | May 12, 2021 | Issued |
Array
(
[id] => 18932329
[patent_doc_number] => 11884736
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-01-30
[patent_title] => Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R)
[patent_app_type] => utility
[patent_app_number] => 17/317056
[patent_app_country] => US
[patent_app_date] => 2021-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 20177
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17317056
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/317056 | Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R) | May 10, 2021 | Issued |
Array
(
[id] => 17085264
[patent_doc_number] => 20210280271
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => DEVELOPING CLASSIFIERS FOR STRATIFYING PATIENTS
[patent_app_type] => utility
[patent_app_number] => 17/315580
[patent_app_country] => US
[patent_app_date] => 2021-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35579
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17315580
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/315580 | Method of treating a subject suffering from rheumatoid arthritis with anti-TNF therapy based on a trained machine learning classifier | May 9, 2021 | Issued |
Array
(
[id] => 17990452
[patent_doc_number] => 20220356489
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => COMPOSITIONS AND METHODS FOR REGULATING PRODUCTION OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 17/313801
[patent_app_country] => US
[patent_app_date] => 2021-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6071
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 22
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17313801
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/313801 | Compositions and method of making a complex able to increase production of a cetuximab-like protein (CLP) in a target cell | May 5, 2021 | Issued |
Array
(
[id] => 20358333
[patent_doc_number] => 12474324
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-18
[patent_title] => Method of making an aromagraph comprising ectopic olfactory receptors
[patent_app_type] => utility
[patent_app_number] => 17/308743
[patent_app_country] => US
[patent_app_date] => 2021-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 14739
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 165
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17308743
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/308743 | Method of making an aromagraph comprising ectopic olfactory receptors | May 4, 2021 | Issued |
Array
(
[id] => 18405828
[patent_doc_number] => 20230167179
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-01
[patent_title] => ANTIBODY AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/921792
[patent_app_country] => US
[patent_app_date] => 2021-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12064
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17921792
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/921792 | ANTIBODY AND USES THEREOF | Apr 29, 2021 | Pending |